跳至主要内容
临床试验/NL-OMON47335
NL-OMON47335已完成3 期

Basilar Artery International Cooperation Study Trial - BASICS Trial

Sint Antonius Ziekenhuis0 个研究点目标入组 180 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
入组人数
180

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • * Symptoms and signs compatible with ischemia in the basilar artery territory
  • * Basilar artery occlusion confirmed by CTA or MRA.
  • * Age18 or older (i.e., candidates must have had their 18th birthday).
  • * If IVT is considered as part of best medical treatment IV rt-PA has to be initiated within 4.5 hours of estimated time of basilar artery occlusion. (Estimated time of basilar artery occlusion is defined as time of onset of acute symptoms leading to clinical diagnosis of basilar artery occlusion or if not known last time patient was seen normal prior to onset of these symptoms * this time is not necessarily the same as the time of onset of first symptoms).
  • * Initiation of IA therapy should be feasible within 6 hours of estimated time of basilar artery occlusion.

排除标准

  • * Pre-existing dependency with mRankin *3.
  • * Females of childbearing potential who are known to be pregnant and/or lactating or who have positive pregnancy tests on admission.
  • * Patients who require hemodialysis or peritoneal dialysis.
  • * Other serious, advanced, or terminal illness.
  • * Any other condition that the investigator feels would pose a significant hazard to the patient if IA therapy is initiated.
  • * Current participation in another research drug treatment protocol (patient cannot start another experimental agent until after 90 days).
  • * Informed consent is not or can not be obtained. ;* Imaging Exclusion Criteria:;* Lesion consistent with hemorrhage of any degree.
  • * Significant cerebellar mass effect or acute hydrocephalus
  • * Bilateral extended brainstem ischemia.

研究者

相似试验